Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case report

JAAD Case Reports

Volumn 1, Issue 1, 2015, Pages 3-4

  Babalola, Olubukola ^a   Lakdawala, Nikita ^a   Strober, Bruce E ^a,b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b PROBITY MEDICAL RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CLOPIDOGREL; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; INSULIN; METFORMIN; METHOTREXATE; USTEKINUMAB;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CASE REPORT; DRUG ELUTING STENT; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; ULTRAVIOLET B RADIATION; UNSTABLE ANGINA PECTORIS;

EID: 84928408421     PISSN: None     EISSN: 23525126     Source Type: Journal    
DOI: 10.1016/j.jdcr.2014.09.002     Document Type: Article

References (8)

1. Hugh J., Van Voorhees A.S., Nijhawan R.I., et al. From the Medical Board of the NationalPsoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impactof current therapies. J Am Acad Dermatol 2014, 70(1):168-177.
2. Henseler T., Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995, 32(6):982-986.
3. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296(14):1735-1741.
4. Wu J.J., Poon K.Y., Channual J.C., Shen A.Y. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012, 148(11):1244-1250.
5. Gordon K.B., Langley R.G., Gottlieb A.B., et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012, 132(2):304-314.
6. Tzellos T., Kyrgidis A., Trigoni A., Zouboulis C.C. Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to date. Dermatoendocrinol 2012, 4(3):320-323.
7. Ryan C., Leonardi C.L., Krueger J.G., et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011, 306:864-871.
8. Tzellos T., Kyrgidis A., Zouboulis C.C. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2013, 27(5):622-677.